DHFR and cancer: Considering that CX-4945 is a potential anti-cancer therapeutic agent, in view of our data showing the inhibition of CK2 activity causes the increase of DHFR and SHMT1 protein levels, a possible increased survival of cancer cells should be taken into consideration.